COMPASS Pathways plc(CMPS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CMPS COMPASS Pathways plc

Pre-Mkt 04-07 05:23:29 EDT

5.75

-0.04

-0.69%

High5.87	Low5.67	Vol1.16M
Open5.80	D1 Closing5.79	Amplitude3.45%
Mkt Cap741.31M	Tradable Cap586.50M	Total Shares128.92M
T/O6.67M	T/O Rate1.14%	Tradable Shares102.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CMPS","market":"US","secType":"STK","nameCN":"COMPASS Pathways plc","latestPrice":5.75,"timestamp":1775505600000,"preClose":5.79,"halted":0,"volume":1159789,"delay":0,"changeRate":-0.0069084628670120956,"floatShares":102000000,"shares":128923295,"eps":-3.08,"marketStatus":"Pre-Mkt","change":-0.04,"latestTime":"04-07 05:23:29 EDT","open":5.8,"high":5.87,"low":5.67,"amount":6672306.2456994,"amplitude":0.034542,"askPrice":6,"askSize":4,"bidPrice":5.35,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.08,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1775568600000},"marketStatusCode":1,"adr":0,"adrRate":1,"listingDate":1600401600000,"exchange":"NASDAQ","adjPreClose":5.75,"postHourTrading":{"tag":"盘后","latestPrice":5.75,"preClose":5.75,"latestTime":"19:44 EDT","volume":12922,"amount":74265.3792,"timestamp":1775519092757,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7535217307810459,"impliedVol":0.7711,"impliedVolPercentile":0.0763},"requestUrl":"/m/hq/s/CMPS","defaultTab":"news","newsList":[{"id":"2622847323","title":"LifeSci Capital Keeps Their Buy Rating on COMPASS Pathways (CMPS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622847323","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622847323?lang=en_us&edition=fundamental","pubTime":"2026-03-28 22:37","pubTimestamp":1774708643,"startTime":"0","endTime":"0","summary":"In a report released today, Francois Brisebois from LifeSci Capital maintained a Buy rating on COMPASS Pathways, with a price target of $19.00. Bri...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lifesci-capital-keeps-their-buy-rating-on-compass-pathways-cmps-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lifesci-capital-keeps-their-buy-rating-on-compass-pathways-cmps-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622262861","title":"Compass Pathways Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2622262861","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622262861?lang=en_us&edition=fundamental","pubTime":"2026-03-26 23:15","pubTimestamp":1774538100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CMPS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2026 11:15 ET (15:15 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622884804","title":"RBC Capital Reaffirms Their Buy Rating on COMPASS Pathways (CMPS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622884804","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622884804?lang=en_us&edition=fundamental","pubTime":"2026-03-26 09:48","pubTimestamp":1774489734,"startTime":"0","endTime":"0","summary":"In a report released on March 24, Leonid Timashev from RBC Capital maintained a Buy rating on COMPASS Pathways, with a price target of $21.00. The ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-reaffirms-their-buy-rating-on-compass-pathways-cmps-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-reaffirms-their-buy-rating-on-compass-pathways-cmps-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622000322","title":"Compass Pathways price target lowered to $18 from $20 at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2622000322","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622000322?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:35","pubTimestamp":1774474515,"startTime":"0","endTime":"0","summary":"Canaccord lowered the firm’s price target on Compass Pathways (CMPS) to $18 from $20 and keeps a Buy rating on the shares. Published first on TheFl...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/compass-pathways-price-target-lowered-to-18-from-20-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/compass-pathways-price-target-lowered-to-18-from-20-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622005002","title":"Compass Pathways Is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2622005002","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622005002?lang=en_us&edition=fundamental","pubTime":"2026-03-26 01:47","pubTimestamp":1774460820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CMPS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2026 13:47 ET (17:47 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622033190","title":"Oppenheimer Sticks to Their Buy Rating for COMPASS Pathways (CMPS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622033190","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622033190?lang=en_us&edition=fundamental","pubTime":"2026-03-26 00:26","pubTimestamp":1774455997,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Jay Olson maintained a Buy rating on COMPASS Pathways today and set a price target of $20.00. Olson covers the Healthcare secto...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-their-buy-rating-for-compass-pathways-cmps-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-their-buy-rating-for-compass-pathways-cmps-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622407278","title":"COMPASS Pathways (CMPS) Receives a Buy from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2622407278","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622407278?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:25","pubTimestamp":1774448752,"startTime":"0","endTime":"0","summary":"In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on COMPASS Pathways, with a price target of $70.00. Trucc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/compass-pathways-cmps-receives-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/compass-pathways-cmps-receives-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622075874","title":"Compass Pathways price target lowered to $16 from $18 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2622075874","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622075874?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:15","pubTimestamp":1774440917,"startTime":"0","endTime":"0","summary":"Morgan Stanley lowered the firm’s price target on Compass Pathways (CMPS) to $16 from $18 and keeps an Overweight rating on the shares after the co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/compass-pathways-price-target-lowered-to-16-from-18-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/compass-pathways-price-target-lowered-to-16-from-18-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0795875169.SGD","LU1244550221.USD","LU1244550494.USD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU1668664300.SGD","BK4534","LU1720051017.SGD","BK4516","LU0557290698.USD","CMPS","LU1548497426.USD","BK4127","LU1732799900.SGD","LU0006306889.USD","BK4504","LU1989772840.SGD","LU0320765646.SGD","BK4585","LU0528227936.USD","LU2089283258.USD","LU2023251221.USD","BK4588","LU1989772923.USD","LU0912757837.SGD","LU0882574139.USD","LU0158827781.USD","LU2089284900.SGD","LU1732800096.USD","LU0267386448.USD","LU0314104364.USD","BK4581","LU1244550577.SGD","LU1720051108.HKD","LU1791710400.SGD","LU0234570918.USD","LU0106831901.USD","LU1363072403.SGD","LU1074936037.SGD","LU0971096721.USD","BK4139","LU2347655156.SGD","LU1162221912.USD","LU2111349929.HKD","LU2133065610.SGD","LU0098860793.USD","LU2271345857.HKD","LU0158827948.USD","LU1791710582.SGD","LU0795875086.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621095649","title":"Compass Pathways Stock Falls on Widened 4Q Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2621095649","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621095649?lang=en_us&edition=fundamental","pubTime":"2026-03-24 22:40","pubTimestamp":1774363200,"startTime":"0","endTime":"0","summary":"Shares of Compass Pathways fell after the company recorded a wider-than-expected fourth-quarter loss.Shares were down 3.3% to $5.17 in Tuesday morning trading. The stock is up 66% over the past year.The biotechnology company on Tuesday reported a loss of $93.9 million, or $1 a share, compared with a loss of $43.3 million, or 63 cents a share, a year earlier.Analysts surveyed by FactSet were expecting a loss of 40 cents a share.Operating expenses fell to $46 million, from $48.4 million a year earlier. The company also recorded a $38.2 million decrease in the fair value of warrant liabilities in the most recent quarter.The company, which is developing COMP360, a psychedelic treatment for depression, did not post any revenue during the quarter. It is scheduled to meet with the Food and Drug Administration about a New Drug Application submission strategy, and is targeting launch-readiness by the end of this year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621061377","title":"Compass Pathways Q4 EPS $(1.00) Misses $(0.37) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2621061377","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621061377?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:37","pubTimestamp":1774352230,"startTime":"0","endTime":"0","summary":"Compass Pathways (NASDAQ:CMPS) reported quarterly losses of $(1.00) per share which missed the analyst consensus estimate of $(0.37) by 173.22 percent. This is a 58.73 percent decrease over losses of $(0.63) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51427246/compass-pathways-q4-eps-1-00-misses-0-37-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621069064","title":"BRIEF-COMPASS Pathways Q4 EPS USD -1","url":"https://stock-news.laohu8.com/highlight/detail?id=2621069064","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621069064?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:30","pubTimestamp":1774351845,"startTime":"0","endTime":"0","summary":"BRIEF-COMPASS Pathways Q4 EPS USD -1\n\n\nMar 24 (Reuters) - COMPASS Pathways Q4 operating income USD -45.952 million vs. IBES estimate USD -41.6 million.\n\nQ4 operating expenses USD 45.952 million\nQ4 net income USD -93.878 million\nQ4 pretax profit USD -96.612 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nPLXDFCADB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621044069","title":"Compass Pathways Q4 net loss rose 116.7% to USD 93.9 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621044069","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621044069?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:30","pubTimestamp":1774351838,"startTime":"0","endTime":"0","summary":"Compass Pathways published a fourth-quarter and full-year 2025 earnings release, reporting a Q4 net loss of USD 93.9 million and a net loss per share of USD 1.00.Full-year net loss widened to USD 287.9 million, while R&D expense was USD 118.4 million.Q4 net loss increased 116.7% to USD 93.9 million, driven primarily by a USD 38.2 million non-cash loss from fair value changes in warrant liabilities.Cash and cash equivalents were USD 149.6 million at year-end, and debt was USD 31.6 million.Management said it expects 26-week Part B data from the COMP006 study in early Q3 2026 to be the final dataset for an NDA submission and expects its cash position to fund operations into 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Path","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL7nHtkX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621342061","title":"Compass Pathways Plc: Cash Position at March 24 Seen to Be Sufficient to Fund Operating Expense, Capex Requirements Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2621342061","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621342061?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:30","pubTimestamp":1774351801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nPLXDFCADB:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621069217","title":"Compass Pathways Q4 Net Income USD -93.878 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621069217","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621069217?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:30","pubTimestamp":1774351801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nPLXDFCADB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621061883","title":"Press Release: Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2621061883","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621061883?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:30","pubTimestamp":1774351800,"startTime":"0","endTime":"0","summary":"--  COMP360 is the first classic psychedelic1 to consistently achieve a. highly statistically significant result and clinically meaningful effect. in treatment resistant depression , with a generally well-tolerated. --  Across three large trials in TRD, including two positive Phase 3. studies, COMP360's differentiated profile is redefining rapidity and. durability for TRD patients and demonstrating a consistent level of. clinical effect that has never been achieved before. --  Compass will meet with the FDA to confirm alignment on a rolling. submission and review, and expects to complete the NDA submission in Q4. COMP360 will fit seamlessly across diverse healthcare settings at launch. --  Successful $150 million financing in February and exercise of $200. Compass Pathways plc , a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported the fourth quarter and full-year 2025 financial results and business highlights.-- ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","BK4585","BK4588","IND","BK4139","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618999133","title":"Compass Pathways to Join Stifel Virtual CNS Forum Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2618999133","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618999133?lang=en_us&edition=fundamental","pubTime":"2026-03-12 18:30","pubTimestamp":1773311418,"startTime":"0","endTime":"0","summary":"Compass Pathways management will attend the Stifel 2026 Virtual CNS Forum on March 17-18, 2026. The company will participate in a fireside chat on March 18, 2026 at 10:30am ET.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL8ZjP5z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMPS","SF","BK4127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616547358","title":"Compass Pathways Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2616547358","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616547358?lang=en_us&edition=fundamental","pubTime":"2026-03-02 22:00","pubTimestamp":1772460000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CMPS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 02, 2026 09:00 ET (14:00 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616339051","title":"H.C. Wainwright Remains a Buy on COMPASS Pathways (CMPS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616339051","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616339051?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:56","pubTimestamp":1772452589,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on COMPASS Pathways today and set a price target of $70.00. According to TipRanks,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-compass-pathways-cmps-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-compass-pathways-cmps-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614104812","title":"Compass Pathways Announces Exercise of $200 Million in Outstanding Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2614104812","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614104812?lang=en_us&edition=fundamental","pubTime":"2026-02-26 19:30","pubTimestamp":1772105417,"startTime":"0","endTime":"0","summary":"Compass Pathways plc said holders exercised 35,059,448 warrants issued on Jan. 13, 2025, generating about $200 million in proceeds. The company will issue 15,160,619 American Depositary Shares and, in lieu of ADSs to certain institutional investors, pre-funded warrants to buy up to 19,898,829 ADSs. Compass said it plans to use the proceeds to fund ongoing Phase 3 trials, a Phase 2b/3 PTSD trial, commercial readiness activities, and general corporate purposes, and expects its cash runway to extend into 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief via Business Wire  on February 26, 2026, and is solely responsible for the information contained the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDLbyzNJv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614303048","title":"Analysts Are Bullish on Top Healthcare Stocks: Geron (GERN), COMPASS Pathways (CMPS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614303048","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614303048?lang=en_us&edition=fundamental","pubTime":"2026-02-26 02:20","pubTimestamp":1772043608,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Geron (GERN – Research Report) and COMPASS Pathways ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-geron-gern-compass-pathways-cmps-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-geron-gern-compass-pathways-cmps-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLSX","CMPS","XBI","BK4112","BK4581","BLSG","LU0029874061.USD","LU0128526141.USD","BK4588","BK4137","BK4585","GERN","LABU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.compasspathways.com","stockEarnings":[{"period":"1week","weight":0.0973},{"period":"1month","weight":-0.1261},{"period":"3month","weight":-0.1844},{"period":"6month","weight":-0.1288},{"period":"1year","weight":1.1218},{"period":"ytd","weight":-0.1667}],"compareEarnings":[{"period":"1week","weight":0.0427},{"period":"1month","weight":-0.02},{"period":"3month","weight":-0.0475},{"period":"6month","weight":-0.0211},{"period":"1year","weight":0.3041},{"period":"ytd","weight":-0.0337}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.053854},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.067409},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.124725},{"month":4,"riseRate":0.5,"avgChangeRate":-0.007072},{"month":5,"riseRate":0.4,"avgChangeRate":-0.043784},{"month":6,"riseRate":0.6,"avgChangeRate":-0.018137},{"month":7,"riseRate":0.8,"avgChangeRate":0.262657},{"month":8,"riseRate":0.4,"avgChangeRate":-0.005792},{"month":9,"riseRate":0.2,"avgChangeRate":-0.10118},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.009194},{"month":11,"riseRate":0.333333,"avgChangeRate":0.034765},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.01163}],"exchange":"NASDAQ","name":"COMPASS Pathways plc","nameEN":"COMPASS Pathways plc","securityTypeName":"DR","adrRate":"1:1"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"COMPASS Pathways plc(CMPS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest COMPASS Pathways plc(CMPS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"COMPASS Pathways plc,CMPS,COMPASS Pathways plc股票,COMPASS Pathways plc股票老虎,COMPASS Pathways plc股票老虎国际,COMPASS Pathways plc行情,COMPASS Pathways plc股票行情,COMPASS Pathways plc股价,COMPASS Pathways plc股市,COMPASS Pathways plc股票价格,COMPASS Pathways plc股票交易,COMPASS Pathways plc股票购买,COMPASS Pathways plc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"COMPASS Pathways plc(CMPS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest COMPASS Pathways plc(CMPS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}